Pacer Advisors Inc. Buys 68,384 Shares of Medpace Holdings, Inc. $MEDP

by · The Cerbat Gem

Pacer Advisors Inc. boosted its stake in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 159.4% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 111,290 shares of the company’s stock after buying an additional 68,384 shares during the period. Pacer Advisors Inc. owned approximately 0.40% of Medpace worth $57,221,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the stock. Portside Wealth Group LLC grew its position in shares of Medpace by 2.5% in the second quarter. Portside Wealth Group LLC now owns 1,090 shares of the company’s stock valued at $342,000 after purchasing an additional 27 shares during the last quarter. M&T Bank Corp grew its holdings in Medpace by 3.4% in the 2nd quarter. M&T Bank Corp now owns 939 shares of the company’s stock valued at $295,000 after buying an additional 31 shares in the last quarter. PDS Planning Inc increased its position in Medpace by 1.5% during the 2nd quarter. PDS Planning Inc now owns 2,421 shares of the company’s stock worth $760,000 after buying an additional 35 shares during the period. Front Row Advisors LLC lifted its holdings in shares of Medpace by 0.4% during the second quarter. Front Row Advisors LLC now owns 9,441 shares of the company’s stock worth $2,963,000 after buying an additional 35 shares in the last quarter. Finally, Geneos Wealth Management Inc. lifted its holdings in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after buying an additional 37 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

MEDP has been the topic of a number of recent research reports. Zacks Research raised shares of Medpace from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 27th. BMO Capital Markets began coverage on shares of Medpace in a research report on Thursday, November 13th. They set a “market perform” rating and a $600.00 target price on the stock. Truist Financial set a $555.00 price target on shares of Medpace in a research report on Monday, October 27th. TD Cowen boosted their price target on Medpace from $356.00 to $462.00 and gave the company a “sell” rating in a research note on Friday, October 24th. Finally, Barclays raised their price objective on Medpace from $485.00 to $525.00 and gave the stock an “underweight” rating in a research note on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, ten have issued a Hold rating and four have issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $490.82.

Read Our Latest Report on MEDP

Insider Transactions at Medpace

In related news, President Jesse J. Geiger sold 21,503 shares of Medpace stock in a transaction that occurred on Wednesday, November 5th. The shares were sold at an average price of $595.66, for a total transaction of $12,808,476.98. Following the sale, the president directly owned 15,000 shares of the company’s stock, valued at approximately $8,934,900. The trade was a 58.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO August J. Troendle sold 59,025 shares of the company’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $607.78, for a total transaction of $35,874,214.50. Following the transaction, the chief executive officer owned 774,602 shares of the company’s stock, valued at approximately $470,787,603.56. This represents a 7.08% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 387,925 shares of company stock valued at $233,386,647. 20.30% of the stock is currently owned by insiders.

Medpace Trading Down 0.8%

Shares of Medpace stock opened at $567.56 on Friday. The company has a market cap of $15.99 billion, a PE ratio of 39.69, a price-to-earnings-growth ratio of 2.16 and a beta of 1.43. The company has a 50 day moving average of $579.62 and a 200-day moving average of $480.17. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $626.26.

Medpace (NASDAQ:MEDP – Get Free Report) last announced its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, beating the consensus estimate of $3.50 by $0.36. The business had revenue of $659.90 million during the quarter, compared to the consensus estimate of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The company’s revenue was up 23.7% on a year-over-year basis. During the same period in the previous year, the business earned $3.01 earnings per share. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. Research analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Profile

(Free Report)

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

Further Reading